Nonvariceal Upper GI Bleed — Endoscopy and PPI

Key Points

• Resuscitate first, but do not delay endoscopy unnecessarily once the patient is stabilized.
• A restrictive red-cell transfusion threshold around 7 g/dL is appropriate for most patients, with individualized exceptions.
• Risk stratification helps identify the small group safe for outpatient management.
• High-risk ulcer stigmata require endoscopic hemostasis.
• Epinephrine injection alone is not adequate definitive ulcer hemostasis.
• High-dose PPI therapy follows successful endoscopic treatment of high-risk ulcer bleeding.
• Repeat endoscopy is generally preferred for recurrent ulcer bleeding before surgery.
• H. pylori eradication and NSAID/antithrombotic management are essential recurrence-prevention measures.

Algorithm

1. Assess airway, circulation, ongoing bleeding, and shock; establish large-bore IV access and type/crossmatch when severe.
2. Obtain CBC, chemistry, liver tests, and relevant coagulation studies and apply a validated risk score when stable enough.
3. Use restrictive transfusion for most patients while individualizing for shock and cardiovascular ischemia.
4. Start PPI therapy and use erythromycin before endoscopy when a stomach full of blood/clot is likely.
5. Perform upper endoscopy within 24 hours after resuscitation and provide endoscopic hemostasis for high-risk lesions.
6. Continue high-dose PPI after successful ulcer hemostasis.
7. For rebleeding, repeat endoscopic therapy; escalate to arterial embolization or surgery if endoscopic control fails.
8. Identify H. pylori and modify NSAID, aspirin, and anticoagulant risk before discharge.

Clinical Synopsis & Reasoning

Initial assessment determines severity before source. Look for orthostasis, syncope, tachycardia, hypotension, altered mental status, ongoing hematemesis, and comorbid cardiac or liver disease. A normal hemoglobin early in acute hemorrhage does not exclude major blood loss because equilibration takes time. Melena strongly suggests an upper source, but right-sided colonic bleeding can occasionally mimic it; brisk upper-GI hemorrhage can present as hematochezia. Ask about NSAIDs, aspirin, anticoagulants, prior ulcer disease, H. pylori, alcohol, liver disease, and prior GI bleeding.

Differentiate nonvariceal bleeding from suspected variceal hemorrhage because vasoactive therapy, antibiotics, and endoscopic strategy differ. Peptic ulcers are the dominant nonvariceal cause, but erosive gastritis, esophagitis, Mallory-Weiss tear, malignancy, Dieulafoy lesion, and angioectasia are important alternatives. Risk scores such as Glasgow-Blatchford help identify very-low-risk patients who may be discharged with outpatient follow-up, but unstable patients require resuscitation and endoscopy regardless of score.

Obtain CBC, type and screen or crossmatch, metabolic panel, liver tests, coagulation studies when relevant, and serial hemoglobin. BUN can rise disproportionately from digestion and absorption of blood but is not diagnostic. Nasogastric lavage is not routinely required. Correct severe coagulopathy according to the specific anticoagulant and bleeding severity rather than normalizing every mildly abnormal laboratory value.

Treatment Strategy & Disposition

Establish large-bore IV access and resuscitate with balanced crystalloid while arranging blood products for significant hemorrhage. The ACG guideline supports a restrictive transfusion threshold near hemoglobin 7 g/dL for most hospitalized UGIB patients, with individualized higher thresholds for active ischemia, severe cardiovascular disease, persistent shock, or ongoing massive bleeding. Avoid excessive crystalloid that dilutes clotting factors and worsens edema. Reverse life-threatening anticoagulant-associated bleeding using agent-specific strategies while balancing thrombosis risk.

Give IV PPI therapy in significant suspected ulcer bleeding. Pre-endoscopic PPI can downstage endoscopic stigmata but should not delay endoscopy. After successful endoscopic hemostasis of a high-risk ulcer, high-dose PPI therapy for 72 hours is recommended, followed by an oral regimen. IV erythromycin shortly before endoscopy can improve gastric visualization when substantial retained blood or clot is expected. Routine octreotide is not needed for nonvariceal hemorrhage but should be started when variceal bleeding remains plausible.

Perform upper endoscopy within 24 hours after presentation once adequate resuscitation has occurred, sooner for ongoing instability when the airway and circulation are controlled. Endoscopic therapy is indicated for active spurting or oozing and nonbleeding visible vessels; epinephrine injection should not be used as sole definitive therapy. Recurrent bleeding usually receives repeat endoscopy, followed by transcatheter arterial embolization if endoscopic treatment fails. Surgery remains important when embolization is unavailable or unsuccessful. Test for and eradicate H. pylori and discontinue avoidable ulcerogenic drugs.

Epidemiology / Risk Factors

• Peptic ulcer disease is a leading cause of nonvariceal UGIB.
• NSAIDs, aspirin, H. pylori, anticoagulants, and older age increase bleeding risk.
• Mortality is concentrated among older patients with shock and major comorbidity rather than from endoscopic lesion appearance alone.
• Modern endoscopic therapy and acid suppression have reduced surgery rates.
• Rebleeding remains an important early complication after high-risk ulcer hemorrhage.

Investigations

Pre-Endoscopy Medications

Pharmacology

Prognosis / Complications

• Most patients achieve durable hemostasis with endoscopic therapy and PPI treatment.
• Shock, ongoing transfusion requirement, severe comorbidity, and rebleeding worsen prognosis.
• Failure of two endoscopic attempts often signals need for interventional radiology or surgery.
• H. pylori eradication markedly reduces recurrent ulcer bleeding.
• Long-term prognosis depends on safe management of antithrombotic and NSAID exposure.

Patient Education / Counseling

• Return immediately for recurrent vomiting of blood, black stools with weakness, syncope, chest pain, or shortness of breath.
• Avoid NSAIDs unless the treating clinician has specifically determined they are necessary and protected by an appropriate strategy.
• Complete H. pylori eradication therapy and confirm eradication when recommended.
• Take PPI therapy for the prescribed duration after ulcer treatment.
• Do not independently stop or restart aspirin, anticoagulants, or antiplatelet drugs; coordinate with GI and the prescribing cardiovascular clinician.
• Avoid excess alcohol and smoking because both can complicate ulcer healing and overall GI health.

Notes

The ACG 2021 upper-GI and ulcer-bleeding guideline supports endoscopy within 24 hours, restrictive transfusion for most patients, evidence-based endoscopic hemostasis, and high-dose PPI after treatment of high-risk ulcers.

Acute hemostasis and recurrence prevention are inseparable. H. pylori treatment, NSAID decisions, and appropriate resumption of antithrombotic therapy determine much of the risk after discharge.

References

1. ACG Upper Gastrointestinal and Ulcer Bleeding Guideline 2021 — Link
2. ACG Clinical Guidance on Anticoagulants During GI Bleeding — Link